Malherbe Tayla, Odendaal Anneze, Hille Jos, van Rensburg Leon Janse, Meyer Mark, Myburgh Etienne, Afrogheh Amir H
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of the Western Cape, Cape Town, South Africa.
Department of Oral Medicine and Periodontology, Faculty of Dentistry, University of the Western Cape, Cape Town, South Africa.
Head Neck Pathol. 2025 Feb 5;19(1):15. doi: 10.1007/s12105-024-01737-z.
The recent World Health Organization (WHO) classification of odontogenic tumours defines Sclerosing Odontogenic Carcinoma (SOC) as a rare primary intraosseous carcinoma (PIOC) of the jaws. With the exception of one case, there have been no cases of SOC with metastatic disease. We report a unique case of SOC with neck node metastases, further expanding the clinical, radiological and histological spectrum of this rare intriguing tumour.
A 52-year-old female presented with a destructive radiolucent lesion of right mandible. Incisional biopsy was interpreted as desmoplastic ameloblastoma. The segmental mandibulectomy specimen was histologically consistent with SOC with positive anterior margin. Further resection with neck dissection revealed positive right levels IB and IIA nodes. Immunohistochemistry and Fluroscent In Situ Hybridization (FISH) were performed to confirm the diagnosis.
The tumour was positive for CK5, p63, p40 and negative for CK19, CK20, CK7, SOX-10, S100, ER, PR, BRAFV600E, and EWSR1 gene rearrangements. Ki67 was 15%.
To avoid confusion with PIOC, a high grade squamous cell carcinoma of the jaws with poor prognosis, SOC may be best defined as a rare infiltrative and locally aggressive odontogenic carcinoma with metastatic potential but with a reasonably favourable outcome. SOC shares similar histologic features with many benign and malignant tumours. An appropriate panel of immunohistochemical markers, in conjunction with special stains and molecular studies can help refine the differential diagnosis. It appears that a Ki67 proliferation index of more than 10%, may pose a risk for nodal metastasis and may assist in planning the clinical management. To achieve lower rates of positive margins and tumour recurrence, a wider resection margin (more than a centimetre) is recommended.
世界卫生组织(WHO)近期对牙源性肿瘤的分类将硬化性牙源性癌(SOC)定义为一种罕见的颌骨原发性骨内癌(PIOC)。除1例病例外,尚无SOC伴转移疾病的病例报告。我们报告1例独特的伴有颈部淋巴结转移的SOC病例,进一步拓展了这种罕见且引人关注肿瘤的临床、影像学和组织学谱。
一名52岁女性,右侧下颌骨出现溶解性骨质破坏病变。切开活检结果诊断为促结缔组织增生性成釉细胞瘤。下颌骨节段性切除标本的组织学表现符合SOC,前缘阳性。进一步行颈部清扫术切除显示右侧ⅠB和ⅡA区淋巴结阳性。进行免疫组织化学和荧光原位杂交(FISH)以确诊。
肿瘤CK5、p63、p40呈阳性,CK19、CK20、CK7、SOX - 10、S100、雌激素受体(ER)、孕激素受体(PR)、BRAFV600E及EWSR1基因重排呈阴性。Ki67为15%。
为避免与预后较差的颌骨高级别鳞状细胞癌PIOC相混淆,SOC或许最好定义为一种罕见的具有浸润性和局部侵袭性、有转移潜能但预后相对较好的牙源性癌。SOC与许多良性和恶性肿瘤具有相似的组织学特征。一组合适的免疫组织化学标志物,结合特殊染色和分子研究,有助于完善鉴别诊断。似乎Ki67增殖指数超过10%可能提示有淋巴结转移风险,并有助于规划临床治疗。为降低切缘阳性率和肿瘤复发率,建议切除边缘更宽(超过1厘米)。